Stockscreener 앱 받기
4.38
0.68%
-0.03
시간 외 거래:
4.39
0.010
+0.23%
Humacyte Inc 주식(HUMA)의 최신 뉴스
HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025Contact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA) - Business Wire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Humacyte, Inc. - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors With Large Losses in Humacyte, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewswire Inc.
Insider Buyers At Humacyte Likely Disappointed With 17% Slide - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In HUMA To Contact Him Directly To Discuss Their Options - PR Newswire
Humacyte announces publication of results on ATEV - TipRanks
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery - The Manila Times
Humacyte director Brady Dougan buys $7,978 in common stock - Investing.com
Humacyte CEO Laura Niklason buys shares worth $7,978 - Investing.com
Humacyte director Brady Dougan sells shares worth $6.6 million - Investing.com
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Humacyte CEO Laura Niklason sells $6.6m in common stock - Investing.com
Humacyte director Brady Dougan sells shares worth $6.6 million By Investing.com - Investing.com UK
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. (HUMA) - EIN News
HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Blood Vessel Maker Faces Investor Suit Over FDA Findings - Law360
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Humacyte, Inc. - PR Newswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholder lawsuit shines light on biotech's FDA woes - The Business Journals
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues– Hagens Berman - GlobeNewswire
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. - Business Wire
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - The Manila Times
Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV?? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - Marketscreener.com
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
HC Wainwright Decreases Earnings Estimates for Humacyte - MarketBeat
Humacyte Advances with $15M Direct Offering - TipRanks
Cantor Fitzgerald Reduces Earnings Estimates for Humacyte - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Shareholders to Inquire about Securities Investigation - AccessWire
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering - The Manila Times
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Shareholders to Reach Out - AccessWire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Q3 2024 Earnings Call Transcript - Insider Monkey
Humacyte Q3 2024 Earnings Preview - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc.HUMA - cnhinews.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humacyte, Inc. (HUMA) and Encourages Investors to Learn More About the Investigation - AccessWire
Humacyte (NASDAQ:HUMA) Shares Up 11%Time to Buy? - MarketBeat
Humacyte Reports Q3 2024 Results Amid FDA Review - TipRanks
Humacyte Inc (HUMA) Quarterly 10-Q Report - Quartz
Humacyte Third Quarter 2024 Financial Results and Business Update - WICZ
Objective long/short (HUMA) Report - Stock Traders Daily
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Research Analysts Offer Predictions for Humacyte Q3 Earnings - MarketBeat
Humacyte (HUMA) to Release Quarterly Earnings on Friday - MarketBeat
The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Analysts Issue Forecasts for Humacyte FY2028 Earnings - MarketBeat
0.93%
3.55%
자본화:
|
볼륨(24시간):